Related references
Note: Only part of the references are listed.Prediction of tamoxifen outcome by genetic variation of CYP2D6 in post-menopausal women with early breast cancer
Hiltrud Brauch et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Emergence of Constitutively Active Estrogen Receptor-α Mutations in Pretreated Advanced Estrogen Receptor-Positive Breast Cancer
Rinath Jeselsohn et al.
CLINICAL CANCER RESEARCH (2014)
CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations
M. A. Province et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8
Matthew P. Goetz et al.
CLINICAL CANCER RESEARCH (2013)
Tamoxifen Use in Postmenopausal Breast Cancer: CYP2D6 Matters
Hiltrud Brauch et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Concordance Between CYP2D6 Genotypes Obtained From Tumor-Derived and Germline DNA
James M. Rae et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival
Victor J. Weigman et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial and Re: CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients
Paul D. P. Pharoah et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
CYP2D6 Genotype as a Marker for Benefit of Adjuvant Tamoxifen in Postmenopausal Women: Lessons Learned
Catherine M. Kelly et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial
Yusuke Nakamura et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 198 Trial
Vincent Stanto
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients
James M. Rae et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial
Meredith M. Regan et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma
T. E. Muerdter et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Tamoxifen Metabolite Concentrations, CYP2D6 Genotype, and Breast Cancer Outcomes
L. Madlensky et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Comprehensive assessment of array-based platforms and calling algorithms for detection of copy number variants
Dalila Pinto et al.
NATURE BIOTECHNOLOGY (2011)
Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen
Werner Schroth et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers
Richard M. Simon et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Novel candidate tumour suppressor gene loci on chromosomes 11q23-24 and 22q13 involved in human insulinoma tumourigenesis
Y. M. H. Jonkers et al.
JOURNAL OF PATHOLOGY (2006)
A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen
MP Goetz et al.
CLINICAL CANCER RESEARCH (2006)
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes
MP Goetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine
V Stearns et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Share Paper
